A detailed history of Vanguard Group Inc transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Vanguard Group Inc holds 12,200,368 shares of SGMO stock, worth $5.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,200,368
Previous 12,599,129 3.16%
Holding current value
$5.49 Million
Previous $6.8 Million 20.15%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$0.42 - $1.38 $167,479 - $550,290
-398,761 Reduced 3.16%
12,200,368 $8.17 Million
Q4 2023

Feb 14, 2024

BUY
$0.3 - $0.63 $20,665 - $43,396
68,884 Added 0.55%
12,599,129 $6.8 Million
Q3 2023

Nov 14, 2023

BUY
$0.58 - $1.47 $76,463 - $193,794
131,833 Added 1.06%
12,530,245 $7.52 Million
Q2 2023

Aug 14, 2023

SELL
$1.11 - $1.74 $2.2 Million - $3.45 Million
-1,982,497 Reduced 13.79%
12,398,412 $16.1 Million
Q1 2023

May 15, 2023

BUY
$1.66 - $3.67 $556,598 - $1.23 Million
335,300 Added 2.39%
14,380,909 $25.3 Million
Q4 2022

Feb 10, 2023

BUY
$2.77 - $5.07 $3.64 Million - $6.66 Million
1,314,500 Added 10.33%
14,045,609 $44.1 Million
Q3 2022

Nov 14, 2022

BUY
$4.27 - $6.39 $5.15 Million - $7.71 Million
1,205,951 Added 10.46%
12,731,109 $62.4 Million
Q2 2022

Aug 12, 2022

BUY
$3.28 - $6.21 $4.56 Million - $8.63 Million
1,389,297 Added 13.71%
11,525,158 $47.7 Million
Q1 2022

May 13, 2022

BUY
$5.23 - $7.82 $4.16 Million - $6.22 Million
795,306 Added 8.51%
10,135,861 $58.9 Million
Q4 2021

Feb 14, 2022

BUY
$7.29 - $10.97 $1.06 Million - $1.59 Million
145,220 Added 1.58%
9,340,555 $70.1 Million
Q3 2021

Nov 12, 2021

BUY
$9.01 - $12.01 $811,593 - $1.08 Million
90,077 Added 0.99%
9,195,335 $82.9 Million
Q2 2021

Aug 13, 2021

BUY
$10.17 - $12.64 $92.6 Million - $115 Million
9,105,258 New
9,105,258 $109 Million

Others Institutions Holding SGMO

About SANGAMO THERAPEUTICS, INC


  • Ticker SGMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 156,552,992
  • Market Cap $70.4M
  • Description
  • Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...
More about SGMO
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.